(Q43818679)

27 November 2017

Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. (English)

1 reference

27 November 2017

1 reference

1 reference

5

1 reference

27 November 2017

Tatulli I

1

1 reference

27 November 2017

Francavilla R

2

1 reference

27 November 2017

Rizzo GL

3

1 reference

27 November 2017

Vinciguerra V

4

1 reference

27 November 2017

Amoruso A

6

1 reference

27 November 2017

Panella C

7

1 reference

27 November 2017

Francavilla A

8

1 reference

27 November 2017

language of work or name

1 reference

1 December 2001

1 reference

27 November 2017

Journal of Hepatology

1 reference

27 November 2017

35

1 reference

27 November 2017

6

1 reference

27 November 2017

805-810

1 reference

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Precore mutant hepatitis B virus infection and liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Lamivudine therapy for hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Side effects of alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Chronic hepatitis B virus infection: treatment strategies for the next millennium

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

Detection of hepatitis B virus resistance to antivirals

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900201-X

7 January 2021

10.1016/S0168-8278(01)00201-X

Identifiers

DOI

1 reference

27 November 2017

1 reference